IQVIA (IQV)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$267.77-1.42%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Research Workspace
Put IQV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Full-year 2026 revenue at $17.15-$17.35 billion: FY26 rev guidance $17.27B vs $17.15B target.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, guidance credibility, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskIQV's growth in R&D Solutions has to keep compounding to justify the price. Revenue grew 8.7% year over year, and the last quarter beat expectations. IQV trades at 22× P/E versus a peer median of 34×. The price reflects less growth than forecasted, indicating modest expectations. A specific risk is the potential for a credibility hit if IQV cuts guidance after recently raising it. Peer multiples imply a price about 3% above where it trades. The thesis is on watch due to a primary pillar under pressure.
Trailing returns as of 2026-09-04. IQV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering IQV (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for IQV in the last 4 months.
Continue this research
Compare IQV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| IQV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put IQV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand R&D Solutions backlog and net new bookings
Enhances R&D Solutions backlog and net new bookings potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $267.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $267.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Expand R&D Solutions backlog and net new bookings
AI platform boosts R&D Solutions capabilities and market competitiveness.
Advances: Reaffirm and raise full-year 2026 revenue and earnings guidance
Q2 beat and raised guidance supports growth objectives.
Advances: Reaffirm and raise full-year 2026 revenue and earnings guidance
Higher revenue outlook supports growth objectives.
Advances: Expand R&D Solutions backlog and net new bookings
Q2 results indicate strong growth in R&D Solutions backlog.
Advances: Expand R&D Solutions backlog and net new bookings
Record bookings support growth and backlog expansion objectives.
Threatens: Increase share repurchase authorization and execute buybacks
CEO stock sale raises concerns about confidence in the company.
Advances: Reaffirm and raise full-year 2026 revenue and earnings guidance
Q2 results support revenue and earnings guidance for 2026.